Progenics Pharmaceuticals has currently one product on the market, Relistor, and has a deep pipeline that has both early and late-stage product candidates, and is broke down into 4 categories: PSMA targeted oncology, oncology, oncology supportive care, and partnered programs.
PGNX has completed a pre- submission meeting for Azedra with the FDA and an NDA submission should follow this month. The drug has been awarded Breakthrough designation and was developed under a SPA. Top line results were released earlier this year and a fuller data set is expected to be presented at the International Symposium of Pheochromocytoma and Paraganglioma on Sept. 1.
Combined with submission of the NDA for Azedra, this should boost the shares significantly. Taking the combined value of relistor, Azedra, other pipeline assets and cash on hand; Progenics could easily double from current trading levels and still sell for less than its intrinsic value.This valuation discount should be narrowed substantially as the prospects for Progenics become clearer for the market in the coming months.
Trading Progenics Pharmaceuticals
Progenics Pharmaceuticals diskutieren